2005 Aktienübersicht Die SSY Group Limited, eine Investment-Holdinggesellschaft, erforscht, entwickelt, produziert, handelt und verkauft verschiedene pharmazeutische Produkte an Krankenhäuser und Vertriebshändler in der Volksrepublik China und auf internationaler Ebene. Mehr Details
Belohnungen Risikoanalyse Alle Risikoprüfungen anzeigen Erfassen Sie Ihre Gedanken, Links und Unternehmenseinschätzung
SSY Group Limited Wettbewerber Preisentwicklung & Leistung
Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für SSY Group Historische Aktienkurse Aktueller Aktienkurs HK$3.37 52-Wochen-Hoch HK$5.20 52-Wochen-Tief HK$3.26 Beta 0.62 1 Monat Veränderung -5.87% 3 Monate Veränderung -23.41% 1 Jahr Veränderung -31.92% 3 Jahre Veränderung -14.90% 5 Jahre Veränderung -47.59% Veränderung seit IPO 29.12%
Aktuelle Nachrichten und Updates
SSY Group Limited Announces Update on Product Development Dec 30 SSY Group Limited Announces Update on Product Development
SSY Group Limited Announces Update on Product Development Dec 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of China Dec 02
SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency Evaluation Nov 27
SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg) Nov 05 Weitere Updates anzeigen
SSY Group Limited Announces Update on Product Development Dec 30 SSY Group Limited Announces Update on Product Development
SSY Group Limited Announces Update on Product Development Dec 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Compound Sodium Acetate and Glucose Injection from National Medical Products Administration of China Dec 02
SSY Group's Glycerol Fructose and Sodium Chloride Injection Approved by China's National Medical Products Administration for Consistency Evaluation Nov 27
SSY Group Limited Announces Approval for Drug Production and Registration for Phenylephrine Hydrochloride Injection (1ml:10mg) Nov 05
SSY Group Limited Obtains the Approval for Drug Production and Registration for Cycloserine Capsules (0.25G) from the National Medical Products Administration of China Oct 21
SSY Group Limited Cisatracurium Besilate Receives Approval for Market Registration in China Oct 14
Investor sentiment improves as stock rises 18% Oct 02
Chairman & CEO recently bought HK$4.8m worth of stock Sep 25
SSY Group Limited Announces Update on Product Development Sep 09
Chairman & CEO recently bought HK$1.5m worth of stock Sep 04
SSY Group Limited Announces Update on Product Development Sep 02
First half 2024 earnings released: EPS: HK$0.23 (vs HK$0.21 in 1H 2023) Aug 31
First half dividend increased to HK$0.08 Aug 30 SSY Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2024, Payable on 27 September 2024
SSY Group Limited to Report First Half, 2024 Results on Aug 28, 2024 Aug 16
SSY Group Limited Announces Update on Product Development Aug 07
Investor sentiment deteriorates as stock falls 16% Jul 29
SSY Group Limited Announces Update on Product Development Jul 23
SSY Group Limited Announces Update on Product Development Jul 16
SSY Group Limited Announces Update on Product Development Jun 29
SSY Group Limited Announces Update on Product Development Jun 24
SSY Group Limited Obtains Approval for Drug Production and Registration for Esmolol Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China Jun 18
SSY Group Limited Announces Update on Product Development Jun 08 SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China
SSY Group Limited Announces Update on Product Development May 29
Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China May 28
Upcoming dividend of HK$0.10 per share May 14
SSY Group Limited Provides Update on Product Development Apr 03
Chairman & CEO recently bought HK$2.5m worth of stock Mar 29
SSY Group Limited, Annual General Meeting, May 17, 2024 Mar 28
Full year 2023 earnings released: EPS: HK$0.44 (vs HK$0.38 in FY 2022) Mar 28
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024 Mar 27
SSY Group Limited Announces Update on Product Development Mar 21
SSY Group Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 16
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection (12mg) from the National Medical Products Administration of China Mar 02
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market Mar 01
SSY Group Limited Receives Approval for Gliclazide Tablet Feb 28
SSY Group Limited Provides Update on Product Development Feb 24
SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China Feb 19
SSY Group Limited Announces Update on Product Development Jan 31
SSY Group Limited Provides Update on Product Development Jan 24 SSY Group Limited Appoints Liu Wenjun as Non-Executive Director
Ssy Group Limited Provides Update on Product Development Jan 17
SSY Group Limited Announces Update on Product Development Jan 10
SSY Group Limited Obtains Approval for Drug Production and Registration for Ropivacaine Hydrochloride and Sodium Chloride Injection from National Medical Products Administration of China Jan 05
SSY Group Limited Provides Update on Product Development Dec 27
Chairman & CEO recently bought HK$4.7m worth of stock Dec 06
SSY Group Limited Announces Update on Product Development Dec 01
SSY Group Limited Announces Update on Product Development Nov 23
SSY Group Limited Announces Update on Product Development Nov 10
National Medical Products Administration of China Accepts Application for Phase I Clinical Trial of the SSY Group Limited 'S SYN-045 Nov 09
SSY Group Limited Announces Resignation of Feng Hao as Non-Executive Director, Effective from 1 November 2023 Nov 02
SSY Group Limited Obtains Approvals for Drug Production and Registration for Aminophylline Injection Nov 01
SSY Group Limited Announces Update on Product Development Oct 31
SSY Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Tablets from the National Medical Products Administration of China Oct 27
SSY Group Limited Provides Update on Product Development Oct 26
SSY Group Limited Obtains the Clinical Trial Approval Issued By the National Medical Products Administration of China for Alprostadil Injection Oct 21
SSY Group Limited Obtains the Approval for Drug Production and Registration for Linezolid and Sodium Chloride Injection (300ml) from the National Medical Products Administration of China Oct 18
SSY Group Limited Obtains the Approvals for Drug Production and Registration for Tinidazole Tablets (0.5G) and Ornidazole Tablets (0.5G) from the National Medical Products Administration of China Oct 12
SSY Group Limited Announces Update on Product Development Oct 10
SSY Group Limited Announces Update on Product Development Sep 16
Upcoming dividend of HK$0.07 per share at 3.5% yield Sep 07
SSY Group Limited Announces Update on Product Development Sep 05
SSY Group Limited Provides Update on Product Development Sep 02
First half 2023 earnings released: EPS: HK$0.21 (vs HK$0.19 in 1H 2022) Aug 30
Ssy Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 27 September 2023 Aug 30
SSY Group Limited Announces Update on Product Development Aug 24
SSY Group Limited to Report First Half, 2023 Results on Aug 29, 2023 Aug 18
SSY Group Limited Obtains Approval for Drug Production and Registration for Stiripentol for Suspension (500Mg and 250Mg) from the National Medical Products Administration of China Jul 28
SSY Group Limited Obtains Approval for Drug Production and Registration for Oseltamivir Phosphate for Suspension Jul 14
Chairman & CEO recently bought HK$8.3m worth of stock Jul 08
SSY Group Limited Provides Update on Product Development Jul 07
SSY Group Limited Announces Update on Product Development Jun 30
SSY Group Limited Obtains Approval for Drug Production and Registration for Citicoline Sodium Injection from the National Medical Products Administration of China Jun 14
SSY Group Limited Obtains the Approvals for Drug Production and Registration for Urapidil Hydrochloride Injection Jun 03
SSY Group Limited Announces Update on Product Development May 31
SSY Group Limited Announces the Retirement of Mr. Leung Chong Shun as Independent Non-Executive Director, Chairman of the Remuneration Committee of the Company, A Member F the Audit Committee of the Company and A Member of the Nomination Committee May 20
Upcoming dividend of HK$0.08 per share at 2.8% yield May 16
SSY Group Limited Announces Update on Product Development May 13
SSY Group Limited Announces Update on Product Development May 12
Chairman & CEO recently bought HK$4.9m worth of stock May 10
SSY Group Limited Announces Update on Product Development May 09
Chairman & CEO recently bought HK$2.1m worth of stock Mar 30
Full year 2022 earnings released: EPS: HK$0.38 (vs HK$0.26 in FY 2021) Mar 29
Now 21% undervalued Mar 14
SSY Group Limited Announces the Group's Tinidazole Obtains the Approval for Registration from the National Medical Products Administration of China Feb 07
SSY Group Limited Updates on Product Development Jan 31
SSY Group Limited Obtains the Approval for Registration from the National Medical Products Administration of China to Become A Bulk Drug for the Preparations on the Market Jan 20
SSY Group Limited Obtains Approvals for Drug Production and Registration for Felodipine Sustained-Release Tablets (5mg) and Lacosamide Injection (20ml:0.2g) from the National Medical Products Administration of China Jan 06
Investor sentiment improved over the past week Jan 04
SSY Group Limited Announces Appointment of Jiang Guangce as an Independent Non-Executive Director and Member of Audit Committee, Nomination Committee and Remuneration Committee, with Effect from 1 January 2023 Dec 29
Less than half of directors are independent Nov 16
SSY Group Limited Obtains the Approval for Drug Production and Registration for Azithromycin Tablets (0.25G) from the National Medical Products Administration of China, Being Under Type 4 Chemical Drug and Regarded as Passing the Consistency Evaluation Nov 15
SSY Group Limited Obtains the Approval for Drug Productions from the National Medical Products Administration of China Oct 11 Aktionärsrenditen 2005 HK Pharmaceuticals HK Markt 7D -5.9% -0.9% 0.3% 1Y -31.9% -7.7% 19.4%
Vollständige Aktionärsrenditen anzeigen
Rendite im Vergleich zur Industrie: 2005 unter dem Niveau der Branche Hong Kong Pharmaceuticals , die im vergangenen Jahr eine Rendite von -7.7% erzielte.
Rendite vs. Markt: 2005 hinter dem Markt Hong Kong zurück, der im vergangenen Jahr eine Rendite von 19.4 erzielte.
Preisvolatilität Is 2005's price volatile compared to industry and market? 2005 volatility 2005 Average Weekly Movement 5.1% Pharmaceuticals Industry Average Movement 6.2% Market Average Movement 8.4% 10% most volatile stocks in HK Market 17.7% 10% least volatile stocks in HK Market 3.8%
Stabiler Aktienkurs: 2005 hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.
Volatilität im Zeitverlauf: 2005Die wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen Die SSY Group Limited, eine Investment-Holdinggesellschaft, erforscht, entwickelt, produziert, handelt und verkauft verschiedene pharmazeutische Produkte an Krankenhäuser und Händler in der Volksrepublik China und international. Das Unternehmen bietet intravenöse Infusionslösungen an, darunter Weichbeutel ohne PVC, aufrechte Weichbeutel, PP-Kunststoffflaschen und Infusionslösungen in Glasflaschen, sowie Ampulleninjektionen. Darüber hinaus bietet es Injektionen in kleinen Mengen, orale Präparate, Präparate der chinesischen Medizin und biologische Präparate sowie pharmazeutische Massenprodukte und medizinische Materialien an.
Mehr anzeigen SSY Group Limited's Grundlagenzusammenfassung Wie verhalten sich die Erträge und Einnahmen von SSY Group im Vergleich zum Marktanteil des Unternehmens? 2005 grundlegende Statistiken Marktanteil HK$9.97b Gewinn(TTM ) HK$1.37b Umsatz(TTM ) HK$6.47b
7.3x Kurs-Gewinn-Verhältnis
1.5x Kurs-Umsatz-Verhältnis Erträge & Einnahmen Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM) 2005 Gewinn- und Verlustrechnung (TTM ) Einnahmen HK$6.47b Kosten der Einnahmen HK$2.95b Bruttogewinn HK$3.52b Sonstige Ausgaben HK$2.15b Umsatz HK$1.37b
Zuletzt gemeldete Gewinne
Jun 30, 2024
Datum des nächsten Gewinnberichts
k.A.
Gewinn per Aktie (EPS) 0.46 Bruttomarge 54.39% Nettogewinnspanne 21.11% Schulden/Eigenkapital-Verhältnis 47.7%
Wie hat sich 2005 auf lange Sicht entwickelt?
Historische Performance und Vergleiche Dividenden
5.3% Aktuelle Dividendenrendite
Unternehmensanalyse und Finanzdaten Status Daten Zuletzt aktualisiert (UTC-Zeit) Unternehmensanalyse 2025/01/02 03:11 Aktienkurs zum Tagesende 2025/01/02 00:00 Gewinne 2024/06/30 Jährliche Einnahmen 2023/12/31
Datenquellen Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC . Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
Paket Daten Zeitrahmen Beispiel US-Quelle * Finanzdaten des Unternehmens 10 Jahre Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz Konsensschätzungen der Analysten +3 Jahre Finanzielle Vorausschau Kursziele der Analysten Marktpreise 30 Jahre Aktienkurse Dividenden, Splits und Aktionen Eigentümerschaft 10 Jahre Top-Aktionäre Insiderhandel Verwaltung 10 Jahre Das Führungsteam Direktorium Wichtige Entwicklungen 10 Jahre Ankündigungen des Unternehmens
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.
Analysemodell und Schneeflocke Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite . Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube .
Erfahren Sie mehr über das Weltklasse-Team , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .
Analysten-Quellen SSY Group Limited wird von 22 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
Analyst Einrichtung Derrick Sun BNP Paribas Securities (Asia) Milo Liu BOCOM International Securities Limited Ying Shao BofA Global Research
19 weitere Analysten anzeigen 
